NetworkNewsBreaks – Replimune Group Inc. (NASDAQ: REPL) Secures $287.5M in Follow-On
Replimune Group (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, has closed an underwritten public offering of 5,625,000 shares of its common stock, including 937,500 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, each of the shares was sold at the public offering price of $40.00. In addition, in lieu of common stock to certain investors, Replimune also closed a sale of 1,562,500 shares of its common stock at the purchase price of $39.9999 per pre-funded warrant, which equals the public offering price per…







